Spyre Therapeutics (SYRE) Receivables - Accured (2019 - 2026)

Spyre Therapeutics has reported Receivables - Accured for 8 years, with the latest figure at $4.6 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Accured rose 35.29% year-over-year to $4.6 million; the trailing twelve-month figure through Mar 2026 stood at $4.6 million (up 35.29% YoY), and the FY2025 full-year result was $4.5 million, up 32.35% from the prior year.
• Receivables - Accured for Q1 2026 stood at $4.6 million, up from $4.5 million in the prior quarter.
• The five-year high for Receivables - Accured was $4.6 million in Q1 2026, with the low at $100000.0 in Q4 2022.
• Historically, Receivables - Accured has averaged $2.1 million across 5 years, with a median of $1.8 million in 2024.
• Annual changes were most pronounced in 2022 — Receivables - Accured changed 0.0% — and 2024, when it soared 1700.0%.
• Spyre Therapeutics' Receivables - Accured stood at $100000.0 in 2022, then surged by 800.0% to $900000.0 in 2023, then soared by 277.78% to $3.4 million in 2024, then surged by 32.35% to $4.5 million in 2025, then gained by 2.22% to $4.6 million in 2026.
• The last three Receivables - Accured figures came in at $4.6 million (Q1 2026), $4.5 million (Q4 2025), and $3.6 million (Q3 2025), per Business Quant data.